We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -96.00 | -0.79% | 12,060.00 | 12,058.00 | 12,060.00 | 12,098.00 | 12,036.00 | 12,092.00 | 107,889 | 08:47:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.47 | 187.39B |
From May 2019 to May 2024
By Jenny Strasburg
LONDON -- The biotech startup behind the Covid-19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S. regulators for a public share offering.
Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus. The Wall Street Journal reported Wednesday that the IPO filing could come as soon as this week. The U.K.-based company plans to list on New York's Nasdaq with the ticker symbol VACC.
The company was started by two Oxford scientists who helped lead the Covid-19 vaccine development and who spun Vaccitech out of the university in 2016, with the goal of turning laboratory discoveries into commercial products. A key part of the vaccine technology uses an altered form of chimpanzee cold virus to ferry genetic material into humans to boost the immune system and fight infection.
Vaccitech has been aiming for a listed valuation of around $700 million, with backers estimating it could be a $1 billion company by year-end, The Journal reported last month. The company recently raised $168 million in new funding as a step toward a share offering.
It had $4.8 million in revenue last year and a loss of about $17.7 million and hasn't generated any revenue from product sales, according to Friday's filing. It said Vaccitech aims to raise $100 million -- a figure generally put in debut IPO filings as a placeholder to be adjusted during marketing of the company.
Vaccitech to date has raised $216 million from investors including pharmaceutical giant Gilead Sciences Inc.; Alphabet Inc.'s GV, formerly called Google Ventures; and Sequoia Capital China, an affiliate of the Silicon Valley venture-capital giant.
(More to Come)
Write to Jenny Strasburg at jenny.strasburg@wsj.com
(END) Dow Jones Newswires
April 09, 2021 19:06 ET (23:06 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
